A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men

An alternative to currently marketed topical minoxidil solutions is desirable. Objective: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA). Methods: This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF. Results: At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P <.0001) and (2) subjective assessment of improved hair loss condition (P <.0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period. Limitations: There was no collection of efficacy data beyond 16 weeks. Conclusions: We believe that 5% MTF is a safe and effective treatment for men with AGA. (J Am Acad Dermatol 2007;57:767-74.)